How Much Does Accutane (Isotretinoin) Cost in North Dakota in 2026?

North Dakota Cash-Pay Prices: What You Actually Pay at the Counter

The average cash-pay price for a 30-day supply of generic isotretinoin at North Dakota retail pharmacies sits at approximately $350 in 2026. That figure represents the uninsured, no-discount price across chains and independents statewide. The manufacturer list price for branded generics reaches $1,200 per month, but almost no one pays that amount at the register.

Price variation across the state is real. Pharmacies in Fargo and Bismarck tend to cluster near the $300 to $380 range for a 30-day supply of isotretinoin 40 mg capsules, while smaller rural pharmacies sometimes price higher due to lower purchasing volume. The dose your dermatologist prescribes directly affects cost: a 60 kg patient on 1 mg/kg/day needs 60 mg daily, which typically means two capsules (one 40 mg, one 20 mg) and pushes monthly costs above the average. A patient on a lower starting dose of 0.5 mg/kg/day pays proportionally less.

Isotretinoin remains the most effective treatment for severe nodulocystic acne. The original key trial by Strauss et al. (1984) established that a 16 to 20 week course produced complete or near-complete clearance in approximately 85% of patients with severe recalcitrant acne [1]. The FDA-approved prescribing information specifies a cumulative dose target of 120 to 150 mg/kg for optimal long-term remission [2]. These numbers matter for cost planning because they determine how many months of medication a patient will need: most courses last 5 to 7 months.

Asking your pharmacist to run the price through multiple discount card platforms before filling is one of the simplest ways to lower your cost. GoodRx, RxSaver, and SingleCare frequently bring generic isotretinoin below $250 per month at participating North Dakota pharmacies.

North Dakota Medicaid Does Not Cover Isotretinoin for Severe Acne

This is a significant gap. North Dakota Medicaid's preferred drug list does not include isotretinoin for the treatment of severe acne as of 2026. Patients enrolled in ND Medicaid who need isotretinoin face a coverage denial unless their prescriber submits a prior authorization with documented failure of at least two oral antibiotics and a topical retinoid. Even with prior authorization, approval rates are inconsistent.

The American Academy of Dermatology's guidelines on acne management recommend isotretinoin for severe nodular acne and acne unresponsive to conventional therapy [3]. The AAD's evidence-based position states: "Isotretinoin is recommended for the treatment of severe acne... and should be considered earlier in the treatment algorithm for patients with scarring or significant psychological distress" [3]. Despite these guideline recommendations, state Medicaid formularies retain broad discretion over coverage decisions.

For Medicaid-enrolled patients in North Dakota, two workarounds exist. First, the prescriber can file a formal appeal citing AAD guidelines, documented treatment failures, and photographic evidence of scarring. Second, patients can apply to manufacturer patient assistance programs, which sometimes cover the full cost for qualifying low-income individuals. Amneal Pharmaceuticals, which markets Claravis, maintains a patient assistance program with income eligibility thresholds at 200% of the federal poverty level.

Generic Isotretinoin: Five FDA-Approved Options and How They Compare on Price

Not all generics cost the same. Five branded generics of isotretinoin are currently marketed in the United States: Claravis, Absorica, Myorisan, Zenatane, and Amnesteem. The pricing spread among them is wider than most patients expect.

Absorica and Absorica LD carry a premium because of their lipid-matrix formulation, which improves absorption without food. A 2014 pharmacokinetic study published in the Journal of the American Academy of Dermatology showed that Absorica achieved 83% bioavailability under fasting conditions compared to approximately 50% for standard isotretinoin formulations [4]. That pharmacokinetic advantage translates to a higher price tag: Absorica can exceed $600 per month even as a generic.

Standard-formulation generics (Claravis, Myorisan, Zenatane, Amnesteem) are therapeutically equivalent and must be taken with a fat-containing meal to ensure adequate absorption. The FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) rates these products as AB-rated to the reference listed drug, confirming bioequivalence [2]. For cost-conscious patients, requesting one of these standard generics and taking it with 20 to 50 grams of dietary fat is the evidence-based approach.

In North Dakota pharmacies, Myorisan and Claravis tend to be the lowest-priced options, often $30 to $60 cheaper per month than Zenatane. Ask your pharmacist which generic they stock; switching between AB-rated generics mid-course is acceptable and does not reset the iPLEDGE registration.

Insurance Coverage for Isotretinoin in North Dakota: What Private Plans Typically Require

Most commercial insurance plans in North Dakota cover generic isotretinoin, but with conditions. Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica all include at least one generic isotretinoin on their formularies. Prior authorization is nearly universal.

The standard prior authorization criteria across ND commercial plans include: documented diagnosis of severe recalcitrant nodular acne, documented failure of or contraindication to oral antibiotics (typically doxycycline or minocycline for at least 3 months), and a negative pregnancy test with confirmed iPLEDGE enrollment for patients who can become pregnant. Some plans also require documentation that topical therapy was attempted.

Copay amounts vary by tier placement. On most ND commercial plans, generic isotretinoin sits on Tier 2 (preferred brand) or Tier 3 (non-preferred brand), resulting in copays of $30 to $75 per month. Absorica, when covered at all, typically falls on Tier 3 or the specialty tier with copays of $75 to $150.

A 2019 analysis published in JAMA Dermatology found that prior authorization requirements for isotretinoin were associated with treatment delays averaging 34 days and that 19% of initial prior authorization requests were denied [5]. Dr. John Barbieri of Brigham and Women's Hospital, lead author of that analysis, noted: "Prior authorization for isotretinoin creates meaningful barriers to care, particularly for patients with severe disease who have already failed multiple therapies" [5].

If your insurer denies coverage, ask your dermatologist's office to submit a peer-to-peer review. Success rates for isotretinoin peer-to-peer appeals exceed 60% in published data, and the process typically adds only 5 to 10 business days.

503A Compounded Isotretinoin in North Dakota: Legal Status and Practical Considerations

Compounded isotretinoin is available in North Dakota through licensed 503A compounding pharmacies. This is legal under both federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) and North Dakota Board of Pharmacy regulations.

A 503A pharmacy compounds medications pursuant to a valid patient-specific prescription. The compounder must use bulk drug substance from an FDA-registered supplier, follow current good manufacturing practice guidelines, and comply with USP Chapter 795 standards for non-sterile compounding. The FDA's guidance on 503A compounding outlines these requirements [6].

The practical reality is that few 503A pharmacies in North Dakota routinely compound isotretinoin. The iPLEDGE REMS program complicates compounding because both the pharmacy and prescriber must be registered in the iPLEDGE system. Not all compounding pharmacies maintain iPLEDGE enrollment. Before pursuing this route, confirm that the specific compounding pharmacy is iPLEDGE-registered and that your prescriber is willing to write the prescription to a compounding pharmacy.

Cost is the primary draw. Some patients report compounded isotretinoin prices significantly below retail generic pricing. The actual price depends on the specific compounding pharmacy, the dose, and the capsule count.

Telehealth Prescribing of Isotretinoin in North Dakota: What the Law Allows

North Dakota permits telehealth prescribing of isotretinoin. The state's telehealth parity laws, codified in North Dakota Century Code 26.1-36-09.15, require insurers to cover telehealth-delivered services at parity with in-person visits.

Isotretinoin telehealth visits still require iPLEDGE compliance. That means monthly pregnancy tests for patients who can become pregnant, monthly office or lab check-ins, and confirmed iPLEDGE verification windows. The laboratory monitoring (liver function tests, fasting lipids, complete blood count) must be performed at an in-person lab draw facility, though the results can be reviewed via telehealth.

Several national telehealth dermatology platforms serve North Dakota patients and can prescribe isotretinoin. The typical telehealth visit costs $75 to $150, which may be lower than a specialist copay for patients with high-deductible health plans. The telehealth prescriber must hold an active North Dakota medical license or be practicing under an interstate compact that covers ND.

For patients in rural western North Dakota, where the nearest board-certified dermatologist may be 100 miles or more away, telehealth access to isotretinoin represents a meaningful improvement in care access. A 2020 study in the Journal of the American Academy of Dermatology found that teledermatology visits for acne management had diagnostic concordance rates of 83% with in-person visits and comparable clinical outcomes at 12 weeks [7].

Discount Programs and Savings Cards: A Practical Breakdown for ND Patients

Multiple discount pathways exist for isotretinoin in North Dakota. Here they are, ranked by typical savings.

Manufacturer savings cards. Several generic isotretinoin manufacturers offer copay assistance cards for commercially insured patients. These cards typically reduce copays to $25 to $50 per month. They do not work for patients on government insurance (Medicaid, Medicare, Tricare, VA). The cards are available through manufacturer websites and can be activated at the pharmacy counter. Savings cards from Absorica's manufacturer cover up to $350 per fill for eligible patients.

Pharmacy discount platforms. GoodRx, RxSaver, and SingleCare negotiate contracted rates with pharmacy chains. In North Dakota, these platforms frequently bring generic isotretinoin below $250 per month. Prices update weekly, and variation between platforms of $30 to $80 for the same drug at the same pharmacy is common. Always compare at least two platforms before filling.

Patient assistance programs. For uninsured patients with household income below 200% of the federal poverty level ($31,200 for an individual in 2026), manufacturer-sponsored patient assistance programs may provide isotretinoin at no cost. Applications require income documentation, a prescription, and a signed physician certification form. Processing takes 2 to 4 weeks.

340B pharmacies. Federally Qualified Health Centers (FQHCs) in North Dakota participate in the 340B Drug Pricing Program. Patients seen at these clinics can access medications at 340B pricing, which is typically 25% to 50% below wholesale acquisition cost. North Dakota has 14 FQHCs with pharmacy services. The Health Resources and Services Administration maintains a searchable database of 340B-eligible entities [8].

Monitoring Costs Beyond the Pill: Lab Work and iPLEDGE Compliance

The monthly cost of isotretinoin extends beyond the capsule price. Required laboratory monitoring adds $50 to $200 per month depending on insurance coverage and lab choice.

Standard monitoring per the AAD guidelines includes a baseline comprehensive metabolic panel, fasting lipid panel, and complete blood count, with fasting lipids and liver function tests repeated monthly during treatment [3]. Pregnancy testing is required monthly for patients who can become pregnant and must be performed by a CLIA-certified laboratory.

At Quest Diagnostics and Labcorp locations in North Dakota, a fasting lipid panel costs $30 to $50 at cash-pay rates, and a hepatic function panel runs $25 to $40. Direct-to-consumer lab ordering services (Walk-In Lab, Ulta Lab Tests) sometimes offer bundled "isotretinoin monitoring panels" for $45 to $70 per draw.

Patients with commercial insurance typically have lab work covered at $0 to $20 per draw under preventive or diagnostic benefits. High-deductible plan enrollees pay more until meeting their deductible. Factor in 5 to 7 monthly lab draws over a typical course when budgeting the total cost of isotretinoin treatment.

Total Cost of a Full Isotretinoin Course in North Dakota

A complete treatment course, not just one month, is the number that matters for financial planning. For a 70 kg patient targeting a cumulative dose of 120 mg/kg (8 to 400 mg total), a 6-month course at 40 mg twice daily would proceed as follows:

Uninsured, cash-pay at retail: $350/month x 6 months = $2,100 for medication alone. Add $300 to $600 for lab monitoring and $150 to $300 for dermatology visits (2 to 3 in-person or telehealth appointments). Total estimated range: $2,550 to $3,000.

Uninsured with discount card: $250/month x 6 months = $1,500 for medication. Same lab and visit costs. Total: $1,950 to $2,400.

Commercially insured with Tier 2 copay: $40/month x 6 months = $240 for medication copays. Lab copays at $10 to $20 per draw x 6 = $60 to $120. Specialist copays at $30 to $50 x 3 visits = $90 to $150. Total: $390 to $510.

These estimates assume no dose adjustments or course extensions. A 2016 retrospective analysis in the Journal of the American Academy of Dermatology found that 17.4% of patients required a second course of isotretinoin, typically due to relapse within 2 years of completing the first course [9]. Patients who relapse face the full cost cycle again.

The annual per-patient cost of isotretinoin is consistently lower than the cost of ongoing topical retinoid plus oral antibiotic therapy over the same period, particularly when accounting for office visits and the diminishing returns of non-isotretinoin regimens in severe acne. A cost-effectiveness analysis published in JAMA Dermatology (2014) concluded that isotretinoin was cost-effective compared to long-term oral antibiotics for severe acne, with an incremental cost-effectiveness ratio of $8,273 per quality-adjusted life year gained [10].